Biperiden
As of the edition of 20 October 2026, Biperiden is a small molecule: marketed, first approved in 1956 (ES); acts on CHRM1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1997
- Kind
- Small molecule
- Brand name
- Akineton
- First approved
- 1 November 1956 (ES)
- Approvals on record
- 5 in 4 regions
- Holder of the most recent approval
- DESMA PHARMA; 4 holders in all
- Registered trials
- 6, 2 stopped early
- Disease areas
- Mental health; Chemically induced; Nervous system; Injuries
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CHRM1 | Muscarinic acetylcholine receptor M1 | P11229 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 3 | 5 | 2 | 1 | 2 |
| Phase 4 | 1 | 0 | 0 | 0 |
| All trials | 6 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| AbbVie | Acquired holder | 2012 to now |